SAT 3247
Alternative Names: SAT-3247Latest Information Update: 04 Dec 2025
At a glance
- Originator Satellos Bioscience
- Class Small molecules
- Mechanism of Action Adaptor-associated kinase 1 inhibitors
-
Orphan Drug Status
Yes - Duchenne muscular dystrophy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Duchenne muscular dystrophy
- Preclinical Facioscapulohumeral muscular dystrophy; Muscle injury
Most Recent Events
- 14 Nov 2025 Satellos Bioscience files an IND application with the Health Canada to initiate phase II clinical trial for Duchenne muscular dystrophy
- 10 Oct 2025 Adverse events, pharmacokinetics and efficacy data from a phase Ia/b trial in Duchenne muscular dystrophy released by Satellos Bioscience
- 10 Oct 2025 Satellos Bioscience plans a proof-of-concept phase II trial for Duchenne muscular dystrophy (In neonates, In infants, In adolescents, In children) in USA (PO), in 2025